Insights - The FDA just doesn’t want to meet with AcelRx Pharmaceuticals (ACRX). Reported alongside the company’s first quarter financial update, AcelRx’s request for a Type B … Continue Reading
Read NowInsights - Gilead Sciences (GILD) blew past analyst expectations in the first quarter, reporting $7.6 billion in total revenue vs. consensus estimates of $6.9 billion. More important, the company reported an impressive … Continue Reading
Read NowInsights - Shares of Pacira Pharmaceuticals (PCRX) took it on the chin at Thursday’s open as the company completely removed sales guidance for its only marketed product, Exparel. … Continue Reading
Read NowInsights - In a deal valued at $1.275 billion all-in, AstraZeneca (AZN) will partner with Innate Pharma (IPH.PA) for the development of IPH2201, Innate’s anti-NKG2A antibody. For … Continue Reading
Read NowInsights - An unexpected new contender in the race to develop a treatment for NASH (non-alcoholic steatohepatitis) emerged from a European medical conference on Thursday morning – the … Continue Reading
Read NowInsights - Teva (TEVA) made an official bid for rival drugmaker Mylan (MYL), which is in the middle of its own acquisition effort with a $29 billion bid for Perrigo (PRGO).
Read NowInsights - An experimental stem cell treatment from Athersys Inc. (ATHX) failed to improve recovery in patients who had experienced a stroke. ATHX dropped 50% with the data release. … Continue Reading
Read Now
